23 May 2024
23 May 2024
Biogen will bolster its pipeline with felzartamab, a promising immunology asset, through the acquisition.
Research indicates that designing clinical trials with the patient in mind reduces recruitment times and enhances trial performance. Daniel J. Herron, a life sciences specialist, explains why one of the key factors in improving participant involvement is document readability.
Wyost and Jubbonti are approved as biosimilars of reference medicines Xgeva and Prolia.
Evotec will close an Austrian facility as it shuts down its gene therapy business Evotec GT, a move which will affect 40 employees.
The deal bolsters capabilities in viral vector manufacturing for advanced cell and gene therapies.
Rhythm expects Imcivree will be available on the NHS in England and Wales within the next three months.
AstraZeneca has the option to acquire SixPeaks in the next two years if the latter’s bispecific antibody proves successful.
Nona is entitled to receive up to $575m in additional milestone payments.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
